avacincaptad pegol
avacincaptad pegol: sourced relationships with 1 company · 2 clinical trials tracked.
avacincaptad pegol evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could avacincaptad pegol → ISEE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| IVERIC bio, Inc. (ISEE) | Phase 3 |
Clinical Trial Registry Records (2)
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Primary endpoint: The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12
A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Primary endpoint: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence
Frequently asked questions
Which companies have sourced relationships with avacincaptad pegol?
avacincaptad pegol has dated SEC/FDA relationship records for IVERIC bio, Inc..
How many clinical trials involve avacincaptad pegol?
BioSniper tracks 2 clinical trials involving avacincaptad pegol.